• Bristol Myers Squibb reported iza-bren delayed disease progression versus chemotherapy in previously treated EGFR-mutated non-small cell lung cancer in Phase 3 PANKU-Lung01.
• Overall survival results remain immature, although a favorable trend emerged for iza-bren.
• The investigational treatment showed a manageable safety profile, with no new safety signals.
• Results will be presented today at the ESMO 2026 congress in Madrid and simultaneously published in The Lancet.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20261022265969) on October 26, 2026, and is solely responsible for the information contained therein.